Current report No. 48/2021 – Celon Pharma S.A.’s project on the development of innovative therapeutic solutions with the use of RNA technology is granted co-funding

Date prepared: November 2021, time: 2:22 p.m.

Subject: Celon Pharma S.A.’s project on the development of innovative therapeutic solutions with the use of RNA technology is granted co-funding

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.

Content of the report:

The Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on November 29, 2021 it received information that the Company’s application for co-funding of the project entitled “TransformRNA – mRNA Therapeutics generation platform” (the “Project”) submitted to the competition announced by the Medical Research Agency for the commercial clinical trials entitled “Development of innovative therapeutic solutions using RNA technology” (ABM/2021/5), has been selected for co-funding.

Its total cost is estimated at PLN 140 million and the value of co-funding amounts to over PLN 83.5 million.

Project implementation period: from 1 September 2021 to 31 August 2027.

The aim of the Project is to develop clinical candidates based on the mRNA technology in 3 therapeutic areas (oncological diseases, metabolic diseases – AATD deficiency and viral diseases – SARS-CoV-2) and to develop and extend competences of Celon Pharma S.A. in the field of pharmaceutical production in the area of mRNA – initiation and qualification of a sterile production zone in the GMP standard, able to supply the domestic market with vaccines in case of needs arising from the pandemic. The main objectives of the Project are to develop (and deliver to the public) a new generation of therapies in the field of antiviral vaccines, in metabolic and oncological diseases based on mRNA.

The Project's first stage includes basic research intended to confirm and validate therapeutic objectives. In the next stages of preclinical work, mRNA-based medicines will be developed; their safety and efficacy will then be verified in phase I and II clinical trials. In addition, the Project will ensure the improvement and optimisation of the existing manufacturing infrastructure, and selected investments (including the purchase of selected GMP and fill-and-finish line equipment) will allow the production of mRNA products on a scale sufficient for key clinical trials as well as first commercial batches.

The Company will announce the conclusion of the co-funding agreement in a separate current report.